Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer (LAPADO)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Sana-Klinikum Lichtenberg.
Recruitment status was  Recruiting
Information provided by:
Sana-Klinikum Lichtenberg Identifier:
First received: July 28, 2010
Last updated: July 29, 2010
Last verified: July 2010

July 28, 2010
July 29, 2010
September 2007
September 2011   (final data collection date for primary outcome measure)
  • Determine the optimal doses for NPLD, paclitaxel and lapatinib (phase I) [ Time Frame: every 3 weeks ] [ Designated as safety issue: Yes ]
  • Evaluate the pathological response to NPLD, paclitaxel and lapatinib (phase II) [ Time Frame: every 6 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01172223 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer
Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early

Open-label, multicenter phase I/II trial. Patients with HER2-positive (overexpressing or amplified), invasive breast cancer with T1c N1-2 or T2 N0-2 disease will be treated with

  • Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks),
  • Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and
  • Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery) Treatment is planned for 6 cycles unless there is evidence of unacceptable toxicity, disease progression or inadequate efficacy (defined as a decrease in tumor size <25% after 4 courses measured by ultrasound or MR-mammography), or if the patient requested to be released.
Breast cancer is the most common malignancy affecting females in northern Europe and North America, corresponding to an age-corrected annual incidence of 100 to 120 per 100000 females. Approximately 30-40% of all patients treated with curative intent will develop metastatic disease. Perioperative systemic treatment has made a major impact on relapse-free and overall survival of women with early-stage breast cancer [ , ] with therapeutic strategies being based on the endocrine responsiveness and the estimated risk of relapse defined by tumor size, axillary lymph node involvement, histologic and nuclear grade, lymphatic and/or vascular invasion, HER2/neu-overexpression and age [ ]. Perioperative therapy has traditionally been administered postoperatively, but chemotherapy is increasingly utilized in the preoperative setting as it can significantly improve the rate of breast conserving surgery, and new regimens can be evaluated rapidly and more precisely.
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Drug: Lapatinib
Other Name: Tyverb
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
September 2016
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed breast cancer
  • T1c N1-2 or T2 N0-2 disease
  • HER2-positive tumours with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH)
  • No prior systemic treatment regimens for breast cancer
  • Adequate hematologic function (ANC 1500 cells/µl, platelet count 100000/µl, and hemoglobin 8g/dl).
  • Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min
  • Bilirubin level < 1.5 X ULN
  • Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan)
  • Karnofsky performance status 80%
  • Age 18 years
  • If the patient is of childbearing potential, she agrees to: comply with effective contraceptive measures, has been using adequate contraception since the last menses, will use adequate contraception during the study, and has a negative pregnancy test within one week of study entry
  • Written informed consent prior to admission to this study

Exclusion Criteria:

  • Male patients
  • Inflammatory or bilateral breast cancer
  • Evidence of distant metastases
  • Previous systemic or local treatment for breast cancer (including surgery, radiotherapy, cytotoxic and endocrine treatments)
  • Past or current history of other neoplasms, except for
  • Curatively treated non-melanoma skin cancer
  • Adequately treated in situ carcinoma of the cervix
  • Other cancer curatively treated and with no evidence of disease for at least 5 years
  • Significant cardiac disease, including angina pectoris, severe cardiac arrhythmia requiring medication, severe conduction abnormalities, clinically significant valvular disease, cardiomegaly, ventricular hypertrophy, poorly uncontrolled hypertension (resting diastolic blood pressure >115 mmHg), prior myocardial infarction, CHF, or other cardiomyopathy
  • Preexisting sensoric or motor polyneuropathy Grade 2 according to NCI CTC
  • Serious intercurrent medical or psychiatric illness, including serious active infection
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry.
  • Detained persons or prisoners
  • Pregnant or nursing women
18 Years and older   (Adult, Senior)
LAPADO-Study, 2007-000924-42
Not Provided
Not Provided
Prof. Dr. Dirk Elling, Sana Klinikum Lichtenberg
Sana-Klinikum Lichtenberg
Not Provided
Principal Investigator: Dirk Elling Sana Klinikum Lichtenberg, Berlin
Sana-Klinikum Lichtenberg
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP